Advances in new targets for immunotherapy of small cell lung cancer
Thoracic Cancer · 2024-01 · 15 (1) · 3-14
DOI: 10.1111/1759-7714.15178 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Thoracic Cancer, online erschienen am 13.12.2023. Verfasst von Zitong Zheng und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Binzhou Medical University Hospital, Binzhou, P.R. China. Hauptthemen laut MEDLINE: Small Cell Lung Carcinoma, Lung Neoplasms. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 111 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China, National High Level Hospital Clinical Research Funding.
Abstract (Originalsprache)
Small cell lung cancer (SCLC) is one of the highly aggressive malignancies characterized by rapid growth and early metastasis, but treatment options are limited. For SCLC, carboplatin or cisplatin in combination with etoposide chemotherapy has been considered the only standard of care, but the standard first‐line treatment only results in 10‐month survival. The majority of patients relapse within a few weeks to months after treatment, despite the relatively sensitive response to chemotherapy. Over the past decade, immunotherapy has made significant progress in the treatment of SCLC patients. However, there have been limited improvements in survival rates for SCLC patients with the current immune checkpoint inhibitors PD‐1/PD‐L1 and CTLA‐4. In the face of high recurrence rates, small beneficiary populations, and low survival benefits, the exploration of new targets for key molecules and signals in SCLC and the development of drugs with novel mechanisms may provide fresh hope for immunotherapy in SCLC. Therefore, the aim of this review was to explore four new targets, DLL3, TIGIT, LAG‐3, and GD2, which may play a role in the immunotherapy of SCLC to find useful clues and strategies to improve the outcome for SCLC patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology, Binzhou Medical University Hospital, Binzhou, P.R. China.
- Center of Biotherapy, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, P.R. China.
- Department of Medical Oncology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, P.R. China.
- Department of Graduate Work Office, Binzhou Medical University Hospital, Binzhou, P.R. China.
ORCID-Profile: Jiangyong Yu
Förderung
- National Natural Science Foundation of China
- National High Level Hospital Clinical Research Funding
Zitieren
APA
Zheng, Z., Liu, J., Ma, J., Kang, R., Liu, Z., & Yu, J. (2024). Advances in new targets for immunotherapy of small cell lung cancer. Thoracic Cancer, 15(1), 3-14. https://doi.org/10.1111/1759-7714.15178
Vancouver
Zheng Z, Liu J, Ma J, Kang R, Liu Z, Yu J. Advances in new targets for immunotherapy of small cell lung cancer. Thoracic Cancer. 2024;15(1):3-14. doi:10.1111/1759-7714.15178
BibTeX
@article{Zheng2024,
author = {Zheng, Zitong and Liu, Juanjuan and Ma, Junling and Kang, Runting and Liu, Zhen and Yu, Jiangyong},
title = {Advances in new targets for immunotherapy of small cell lung cancer},
journal = {Thoracic Cancer},
year = {2024},
volume = {15},
number = {1},
pages = {3--14},
doi = {10.1111/1759-7714.15178}
}
EUVIMED